EXECUTIVE INTERVIEW – AAIPharma: Making the CDMO a One-Stop-Shop for Manufacturing, Development & Analytical Services
Drug Development Executive: Patrick Walsh, CEO, and Board Director of AAIPharma Services Corp., talks about the role of a CDMO in today’s pharma and biotech space, why companies may choose to partner with a CDMO, and how the company has managed to maintain a leading position in the market.
Degenhard Marx, PhD, and Georges Bouille provide an overview and discussion of the benefits of using intranasal saline, and a range of different devices on the market allowing administration into the nose.
Derek G. Hennecke continues with part 2 on a new 6-part series offering an overview of this yearâ€™s best business books with insights into what they can teach the Pharma industry.
James Fenton says that while the challenges presented by manufacturing pain management products can be significant for some manufacturers, for the right manufacturer, pain management products can present an ideal opportunity.
EXECUTIVE INTERVIEW – Metrics Inc.: Poised for Growth in Contract, Proprietary & Generic Pharmaceuticals
Phil Hodges, who will continue to serve as President of Metrics, talks about how he will guide the company’s future direction and growth, and what the recent transaction means for Metrics, Mayne, and their customers.
MANAGEMENT INSIGHT – Pharming Infertile Fields: Three Strategies for Growth in a Going-Nowhere Economy
In a healthy growing economy, you and I are both business oracles. We plow investments into fertile fields and they grow. Success is a ripe…
ANALYTICAL TESTING – Improvements in Characterization of Pharmaceuticals: Fast Scanning Rate DSC Methods
Kevin P. Menard, PhD, MBA, says fast scanning rate DSC represents a recent and underutilized technique for the characterization of pharmaceutical materials and highlights several of the more common applications.
Frost & Sullivan Analysts Winny Tan, PhD, and Jennifer Brice highlight two dynamic pharmaceutical service segments, CROs and IVD manufacturers, and how they are evolving to meet the growing preclinical and clinical trial needs of pharmaceutical companies. They also discuss open innovation models for outsourcing the earliest stage of drug discovery.
Derek G. Hennecke concludes his 6-part series on lessons learned from other industries.
Dr. Colin Minchom, VP of Hovione’s Particle Design business unit, discusses how the company is evolving and adapting in the current market and reviews its new Particle Design offering.
EXCLUSIVE ONLINE CONTENT
ABITEC Corporation & Larodan AB Announce Brand Refresh After Successful Integration of the Two Companies
ABITEC Corporation, an ABF Ingredients company, recently announced in July 2020 the acquisition of Swedish manufacturer and international marketer of state of the art, high-purity research grade lipids, Larodan AB….
Medrio and PHASTAR recently announced they have partnered to leverage metadata surrounding electronic patient-reported outcomes (ePRO) for advanced data visualization, providing insight into….
In today’s pharmaceutical industry there is a sharp focus on the needs and requirements of the patient. More and more drugs are being developed for specific patient groups. Orphan drugs, for example,….
Fusion Antibodies Partners With Eurofins Discovery to Support Innovative Preclinical Drug Discovery Research
Fusion Antibodies plc recently announced it has entered into a commercial collaboration with Eurofins, a Eurofins Scientific SE (EUFI.PA) group company; a leading provider of products and services to the….
Quotient Sciences, the drug development and manufacturing accelerator, recently announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, UK…..